åêðáéäåõóçó γ.ν.α.

512 Νέοι βιοχημικοί δείκτες στην Καρδιολογία
short-term risk stratification of patiens with acute coronary
syndromes. Clin Chem 1998; 44(3): 494-501.
12. Lindahi B, Diderhoim E, Lagergvist B, et al: Mechanisms
behind the rognostic value of troponi T in unstable
coronary artery disease: a FRISC II substudy. J Am Coll
Card 2001; 38: 979-986.
13. Aviles RJ, Askari AT, Lindahl B, et al: Troponin T levels in
patiens with acute coronary syndromes, with or without
renal dysfunction. N Engl J ed 2002; 346: 2047-2052.
14. Lindahl B, Venge P, Wallentin L: Troponin T identifies
patients with unstable coronary artery disease who
benefit from long-term antithrombotic protection. J Am
Coll Cardiol 1997;29(1):43-48.
15. Lindahl B, Diderholm E, Largerquist B, et al: Effects on
mortality of long term treatment with l.m.w. heparin in
relation to troponin T level and ECG findings – a FRISC
2 substady. Eur Heart J 2000 ; 21 (Suppl.) 521.
16. Setsuta k, Seino Y, Takahashi N et al: Clinical significance
of elevated levels of cardiac troponin T patients with
chronic heart failure Am J Cardiol 1999; 84: 608-611.
17. Sato Y, Kataoka K, Matsumori A et al: Mesuring serum
aminoterminal type III procolagen peptide, 7S domain
of type IV collagen, and cardiac troponin T in patients
with idiopathic dilated cardiomyopathy and secondary
cardiomyopathy. Heart 1997; 78: 505-508.
18. Dierkes J, Domrose U, Westphal S, et al: Cardiac troponin
T predicts mortality in patients with renal disease.
Circulation 2000; 102: 1964-1969.
19. Giannitsis E, Muller-Bardorff M, Kurowski V, et al:
Independent prognostic value of cardiac troponin T in
patiets with confirmed pulmonary embolism. Circulation
2000; 102: 211-217.
20. ver Elst KM, Spapen HD, Nguyen DN, et al: Cardiac Troponin
I & T are biological markers of left verticular dysfunction in
septic shock. Clin Chem 2000; 46: 650-657.
21. Herman EH, Lipshultz SE, Rifai N, et al: Use of cardiac
troponin T levels as an indicator of doxorubicin-induced
cardiotoxicity. Cancer Res 1998; 58: 195-197.
22. Ooi DS, Zimmerman D, Graham J, et al: Cardial troponin
T predicts Long-term outcomes in hemodialysis patiets.
Clin Chem 2001; 47: 412-417.
23. Apple FS: Diagnostic markers for detection of acute
myocardial infraction and reperfusion. Laboratory Medicine
1992; 23: 297-322.
24. Ohman EM, Casey C, Bengtson JR, et al: Early detection
of acute myocardial infraction; additional diagnostic
information from serum concentrations of myoglobin
in patients without ST elevation Br Heart J. 1990; 63:
335-338.
25. Mueller T, et al: Head-to head comparison of the diagnostic
utility of BNP and NT-proBNP in symptomatic
and asymptomatic and structural heart disease Clin
Chim Acta 2004; 341: 41-48.
26. Seino Y, et.al: Application of NT-proBNP and BNP
measurments in cardiac care; a more discerning marker
for the detedction and evaluation of heart failure. Eur J
Heart Fail 2004; 6: 295-300.
27. Bhagavan NV, Lai EM, Rios PA, et al: Evaluation of human
serum albumin cobalt binding assay for the assessment
of myocardial ischemia and myocardial infraction. Clinical
Chemistry 2003; 49(4): 581-585.
28. Sinha MK, Roy D, Gaze D, et al: The role of Ischemia
Modified Albumin (IMA), a new biochemical marker
of myocardial ischemia, in the early diagnosis of acute
coronary syndromes. Emerg Med J 2004; 21: 29-34.
29. Falk RJ, Jennette JC: Antimeutrophil cytoplasmic autoantibodies
with specificity for myeloperoxidase ionpatiens
with systemic vasculitis and idiopathic necotizing and
crescentic glomerulonephritis. N Engl J Med. 1988;
318: 1651-1657.
30. Eikelboom JW, et al: Homocysteine. Ann Intern Med;
1999 ;131; 363-375.
31. Apple FS, Pearce L.A, Chung A, et al: Multiple biomarker
use for detection of adverse events in patients presenting
with symptoms suggestive of acute coronary syndrome.
Clin Chem 2007; 53(5): 874-881.
32. Kazanis K, Manolis A S, Dionyssiou-Asteriou A, et al:
Ischemia Modified Albumin and High-Sensitivity C-Reactive
Protein in coronary atherosclerosis. J Clin Lipid
2008; 2(supp.): S60-S61.
xxxxxxxxxxx
xxxxxx